Drug Discovery & Pharmaceuticals

RSS

Drug Boosts Axon Regrowth In Human Brain-Spinal Cord Model

This study presents a human organoid model that identifies genetic factors limiting nerve regeneration and highlights lynestrenol's role in promoting repair.

4 Jun 2026

Webinar - Modality Agnostic Drug Discovery Strategies for Data Sparse Targets: Lessons Learned From Avammune & Cresset, Hosted by Visioneers

Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to trial-stage candidates in this space.

From Cresset 4 Jun 2026

Bispecific Antibodies Target Tumors While Sparing Healthy Tissue

A new generation of bispecific antibodies effectively targets cancer cells, minimizing toxicity and enhancing treatment precision in preclinical studies.

3 Jun 2026

Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

Redesigning Antibiotics to Overcome Bacterial Efflux Pump Resistance

A new way of designing antibiotics could support the discovery of new treatments for drug-resistant infections.

1 Jun 2026

Nanoparticles Boost Delivery of Lung Cancer Drugs 30-Fold

Lung cancer remains one of the world’s deadliest cancers, yet despite decades of effort to develop new drugs, many fail because they don’t stay in the body long enough to be effective or because they damage healthy organs.

1 Jun 2026

MRM Health Rewarded a € 2.6 M VLAIO Research Grant to Accelerate the Development of Novel Therapeutics that Redefine the Treatment of Immune-Mediated Inflammatory Diseases

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that it has been awarded a research grant of € 2.6M from Flanders Innovation and Entrepreneurship (VLAIO), a government organization with the goal to stimulate economic development in Flanders, Belgium.

29 May 2026

New TriPcide Antibiotics Kill Dormant MRSA Without Resistance

The study on TriPcides reveals their ability to combat MRSA and dormant bacteria, offering a new strategy to address antimicrobial resistance in public health.

27 May 2026

Scientists Synthesize Rare Sea Sponge Molecules to Boost Future Cancer Drug Development

Florida State University chemists have synthesized new molecules derived from bacteria found in a Pacific Ocean sea sponge, a breakthrough for the future of drug development, particularly for rare forms of cancer.

21 May 2026

New 3D Cortical Tissue Models Incorporate Microglia to Bridge Preclinical Translation Gaps

28bio today announced CNS-3D Inflammatory Organoids, designed to evaluate efficacy of anti-inflammatory drugs by quantifying their ability to reduce inflammatory injury, preserve tissue health, and restore neuronal network activity.

20 May 2026

New 3D Human Liver Model Mimics Chronic Disease For 30 Days

Researchers developed a 3D liver model that functions for a month, replicating inflammation and fibrosis, crucial for studying liver diseases and therapies.

19 May 2026

Novel Formicitoxins Found in Carpenter Ant Venom Offer Drug Discovery Impetus

The venom of forest ants and horse ants contains numerous substances that protect the insects from pathogens. Researchers at Martin Luther University Halle-Wittenberg (MLU) and Freie Universität Berlin have succeeded for the first time in identifying and characterizing these novel antimicrobial substances in the insects' venom.

19 May 2026

Restricted Interaction Peptides Change Shape to Lock Therapy Inside Solid Tumors

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target.

14 May 2026

Phesi Analysis of More Than 600,000 Clinical Trial Protocols Finds Less Than a Third are Linked to Patient Data

Phesi, a global provider of patient-centric data science solutions for clinical development, has conducted a global analysis of more than 600,000 clinical trial protocols ahead of ASCO 2026.

From Phesi 13 May 2026

Advanced Molecular Blueprints Guide Development Of Next-Generation Malaria Drugs

Researchers from the Universities of Bath and Leeds (UK) have made a significant advance in the fight against malaria by uncovering a promising new potential target for drug discovery.

7 May 2026

CapyBio Launches New Analysis Services to Improve Cell Identity Engineering

CapyBio, a cell identity tools and services company, today announced the launch of three new commercial analysis services: Capybara™ Benchmarking Analysis, Capybara Advanced Analysis, and CellOracle™ Differentiation Optimization Analysis.

7 May 2026

AI Designs New Antibiotics That Reduce MRSA Infections In Mice

SyntheMol-RL integrates reinforcement learning for antibiotic design, producing synthesizable candidates that show efficacy against MRSA in preclinical models.

5 May 2026

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC).

From MRM Health NV 4 May 2026

New Pipeline Sharpens Single-Cell Profiling of CAR Immune Therapies

CERTOMICS is a Nextflow-based computational pipeline designed to identify and profile CAR-engineered immune cells using single-cell multiomics data. By integrating gene expression, immune receptor profiling, protein markers, CAR-aware references, and CAR-specific quality control, it supports more standardized analysis of adoptive cellular immunotherapies.

29 Apr 2026

Drug Development: Development of Dextran Nanoparticles for Stabilizing Delicate Proteins

Nanoscale Research Letters, an open access journal published under Springer Open, presented a study entitled "Development of Dextran Nanoparticles for Stabilizing Delicate Proteins." In this study, a Brookhaven NanoBrook 90Plus Particle Size Analyzer was used to help develop a novel approach to stabilize and encapsulate proteins into dextran nanoparticles.

From Brookhaven Instruments 29 Apr 2026